Developing the first FDA-approved treatment for premature ejaculation
We are a clinical-stage life sciences company developing novel therapeutics to address areas of significant unmet need in sexual and mental health.
Our lead and pipeline programs
Kadence Bio is developing its lead asset KH-001 as the first FDA-approved treatment for premature ejaculation (PE), and a pipeline of compounds to target mood disorders.
Premature ejaculation at a glance
Driven by our values
Act with Accountability
Keep the goal in mind in every action, make data-driven decisions.
Cultivate People
Foster innovation and learning, celebrate success, respond swiftly to failure.
Practice Reciprocity
Enhance patients’ quality of life, promote social and environmental impact.
News
News and Media Coverage
